Exebacase

N/A

Report date: 2024/04/28 11:22:44

Base Information

Drug NameExebacase
Drug Alias NameCF-301Lysin CF-301
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionCell wall inhibitors
TargetsNot applicable
Therapy Area/IndicationsProsthesis-Related InfectionsEndocarditis, BacterialBacteremia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[14
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Rockefeller University
China Registration ClassN/A

Develop Information

Active CompaniesContrafect Corporation
Inactive CompaniesContrafect
Active IndicationsProsthesis-Related Infections
Inactive IndicationsEndocarditis, BacterialBacteremia

Other Information

ATC CodeN/A
Related LinksN/A